Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vascular endothelial growth factor-121 localised protein delivery - GenVec

Next Previous
X
Search
Drug Profile

Vascular endothelial growth factor-121 localised protein delivery - GenVec

Alternative Names: AdGVVEGF121.10NH; BIOBYPASS; BIOBYPASS® angiogen; BIOBYPASS®-CAD; CI 1023; Vascular endothelial growth factor gene therapy - GenVec

Latest Information Update: 29 Jun 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GenVec
  • Developer Cordis Corporation; GenVec
  • Class Cytokine genes; Gene therapies; Growth factors
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Ischaemic heart disorders
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
  • 04 Oct 2015 Cordis Corporation has been acquired by Cardinal Health
  • 14 Mar 2005 Phase-II clinical trials in Ischaemic heart disorders in Europe (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top